The purpose of this study is to evaluate the effectiveness and safety of an investigational drug called canakinumab in patients with myelofibrosis. Myelofibrosis is a type of cancer which affects the bone marrow and its ability to produce normal blood cells. Recent studies have shown that inflammation plays a role in the growth of abnormal cells that lead to myelofibrosis. Canakinumab, which is a drug given by injection, aims to inhibit the pathways that are a part of this process. Response to the drug will be measured by looking at a reduction of scar tissue forming in bone marrow, blood cell levels, reduction of spleen and liver size, recovery of blood cell formation in bone marrow, and reduction of other symptoms associated with the disease.
What is the full name of this clinical trial?
EIIT2023-MPN-RC122: A Phase 2 study of Canakinumab in patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium